Cordatus Wealth Management’s United Therapeutics UTHR Stock Holding History

Cordatus Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Sell	515 -17	-3%	-$9.57K	0.06%	153
2026 Q1	$315K	Sell	532 -532	-50%	-$265K	0.08%	137
2025 Q4	$518K	Sell	1,064 -3	-0.3%	-$1.4K	0.12%	119
2025 Q3	$447K	Buy	1,067 +4	+0.4%	+$1.34K	0.11%	124
2025 Q2	$305K	Buy	1,063 +4	+0.4%	+$1.2K	0.08%	140
2025 Q1	$326K	Buy	1,059 +28	+3%	+$9.6K	0.09%	122
2024 Q4	$364K	Sell	1,031 -1	-0.1%	-$368	0.1%	116
2024 Q3	$370K	Sell	1,032 -4	-0.4%	-$1.35K	0.13%	97
2024 Q2	$330K	Sell	1,036 -5	-0.5%	-$1.32K	0.12%	103
2024 Q1	$239K	Sell	1,041 -2	-0.2%	-$451	0.17%	53
2023 Q4	$229K	Sell	1,043 -12	-1%	-$2.77K	0.19%	52
2023 Q3	$238K	Sell	1,055 -20	-2%	-$4.61K	0.22%	54
2023 Q2	$237K	Buy	+1,075	New	+$238K	0.09%	140

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Cordatus Wealth Management's UTHR Position: Q2 2026 in Review

Cordatus Wealth Management reduced its United Therapeutics (UTHR) stake by 3.2% in Q2 2026, selling an estimated $9.57K and leaving 515 shares worth $279K. The position accounts for 0.06% of the portfolio, ranked #153.

Cordatus Wealth Management first reported a position in UTHR in Q2 2023 and has held it in 13 quarters since. The position peaked at $518K in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Cordatus Wealth Management held 515 shares of United Therapeutics worth $279K as of Q2 2026.
Cordatus Wealth Management sold 17 United Therapeutics shares in Q2 2026, an estimated $9.57K.
United Therapeutics made up 0.06% of Cordatus Wealth Management's portfolio in Q2 2026, its #153 holding.
Cordatus Wealth Management first reported a position in United Therapeutics in Q2 2023 and has held it in 13 quarters since.
Cordatus Wealth Management's United Therapeutics position peaked at $518K in Q4 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cordatus Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.